{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:16:32Z","timestamp":1782537392064,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alumis Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01727-9","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:09:48Z","timestamp":1775290188000},"page":"2661-2673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Muscianisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Klyachkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Ucpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mera K.","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"7","key":"1727_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628\u201339.","journal-title":"N Engl J Med"},{"issue":"23","key":"1727_CR2","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","volume":"22","author":"R Singh","year":"2021","unstructured":"Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22(23):12793.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1727_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1727_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10(1):102.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1727_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273\u20139.","journal-title":"Mediators Inflamm"},{"issue":"6","key":"1727_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"2","key":"1727_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","volume":"13","author":"G Martin","year":"2023","unstructured":"Martin G. Novel therapies in plaque psoriasis: a review of tyrosine kinase\u00a02 inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417\u201335.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1727_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"key":"1727_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1518681","volume":"13","author":"J Xiong","year":"2025","unstructured":"Xiong J, Xue T, Tong M, Xu L, Bai B. Dynamic trend analysis of global psoriasis burden from 1990 to 2021: a study of gender, age, and regional differences based on GBD 2021 data. Front Public Health. 2025;13:1518681.","journal-title":"Front Public Health"},{"issue":"4","key":"1727_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, et al. Patient perspectives on psoriatic disease burden: results from the global psoriasis and beyond survey. Dermatology. 2023;239(4):621\u201334.","journal-title":"Dermatology"},{"issue":"6","key":"1727_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"},{"key":"1727_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.08.038","author":"J Wei","year":"2025","unstructured":"Wei J, Wang Y, Chen Y, et al. Global burden of psoriasis from 1990 to 2021 and potential factors: a systematic analysis. J Investig Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.08.038.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"1727_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293327","volume":"18","author":"XQ Liu","year":"2023","unstructured":"Liu XQ, Zhou PL, Yin XY, et al. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS ONE. 2023;18(10):e0293327.","journal-title":"PLoS ONE"},{"issue":"1","key":"1727_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34323-4","volume":"13","author":"MT Patrick","year":"2022","unstructured":"Patrick MT, Li Q, Wasikowski R, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1):6565.","journal-title":"Nat Commun"},{"issue":"1","key":"1727_CR15","doi-asserted-by":"publisher","first-page":"16581","DOI":"10.1038\/s41598-019-53017-4","volume":"9","author":"E Lee","year":"2019","unstructured":"Lee E, Han JH, Bang CH, et al. Risk of end-stage renal disease in psoriatic patients: real-world data from a nationwide population-based cohort study. Sci Rep. 2019;9(1):16581.","journal-title":"Sci Rep"},{"issue":"8","key":"1727_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084457","volume":"23","author":"T Tashiro","year":"2022","unstructured":"Tashiro T, Sawada Y. Psoriasis and systemic inflammatory disorders. Int J Mol Sci. 2022;23(8):4457.","journal-title":"Int J Mol Sci"},{"key":"1727_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3899\/jrheum.120237","volume":"89","author":"JM Gelfand","year":"2012","unstructured":"Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24\u20138.","journal-title":"J Rheumatol Suppl"},{"issue":"3 pt 1","key":"1727_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Investig Dermatol. 2012;132(3 pt 1):556\u201362.","journal-title":"J Investig Dermatol"},{"issue":"19","key":"1727_CR19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"1","key":"1727_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1727_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1727_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/24755303241302070","volume":"10","author":"B Strober","year":"2025","unstructured":"Strober B, Zhong Y, Sima A, et al. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council Guidelines in Patients in North America. J Psoriasis Psoriatic Arthritis. 2025;10(1):22\u20137.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1727_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1727_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1727_CR25","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"key":"1727_CR26","unstructured":"Amgen Inc. Otezla (apremilast) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2025."},{"issue":"1","key":"1727_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase\u00a04 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase\u00a0III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1727_CR28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase\u00a04 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase\u00a0III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1727_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1727_CR30","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s13555-023-00975-3","volume":"13","author":"L Schmidt","year":"2023","unstructured":"Schmidt L, Wang CA, Patel V, et al. Early discontinuation of apremilast in patients with psoriasis and gastrointestinal comorbidities: rates and associated risk factors. Dermatol Ther (Heidelb). 2023;13(9):2019\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1727_CR31","volume-title":"Sotyktu (deucravacitinib) [package insert]","author":"Bristol Myers Squibb","year":"2022","unstructured":"Bristol Myers Squibb. Sotyktu (deucravacitinib) [package insert]. Princeton, NJ: Bristol Myers Squibb; 2022."},{"issue":"1","key":"1727_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1727_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase\u00a03 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1727_CR34","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/jdv.20553","volume":"39","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase\u00a03 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025;39(7):1336\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1727_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u00a0years: an open-label extension of randomized clinical trials. JAMA Dermatol. 2025;161(1):56\u201366.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1727_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391","volume":"24","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24(4):3391.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1727_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1727_CR38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ng.2467","volume":"44","author":"LC Tsoi","year":"2012","unstructured":"Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341\u20138.","journal-title":"Nat Genet"},{"issue":"363","key":"1727_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1727_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70094","volume":"17","author":"S Ucpinar","year":"2024","unstructured":"Ucpinar S, Kwan JK, Hoffman JD, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design. Clin Transl Sci. 2024;17(12):e70094.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1727_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaad.2025.07.013","volume":"94","author":"A Blauvelt","year":"2026","unstructured":"Blauvelt A, Arenberger P, Sauder MB, et al. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase\u00a02 study. J Am Acad Dermatol. 2026;94(1):57\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"1727_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104840","volume":"97","author":"LT Jensen","year":"2023","unstructured":"Jensen LT, Attfield KE, Feldmann M, Fugger L. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine. 2023;97:104840.","journal-title":"EBioMedicine"},{"issue":"17","key":"1727_CR43","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","volume":"290","author":"JS Tokarski","year":"2015","unstructured":"Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine kinase\u00a02-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J Biol Chem. 2015;290(17):11061\u201374.","journal-title":"J Biol Chem"},{"issue":"1","key":"1727_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","volume":"86","author":"JG Krueger","year":"2022","unstructured":"Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase\u00a02 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148\u201357.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1727_CR45","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase\u00a02 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763\u201376.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1727_CR46","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type\u00a0I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728\u201335.","journal-title":"Ann Rheum Dis"},{"key":"1727_CR47","unstructured":"Tilley MK, Narayan N, Hoffman JD, et al. ESK-001, an allosteric TYK2 inhibitor, downregulates biomarkers of\u00a0disease and TYK2 activity: biomarker analysis of phase\u00a02 psoriasis study STRIDE [oral presentation]. European Academy of Dermatology and Venereology; September 25\u201328, 2024; Amsterdam, the Netherlands."},{"key":"1727_CR48","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 158715582, envudeucitinib. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Envudeucitinib. Accessed 2025 Nov 17."},{"issue":"20","key":"1727_CR49","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1021\/acs.jmedchem.9b00443","volume":"62","author":"R Moslin","year":"2019","unstructured":"Moslin R, Zhang Y, Wrobleski ST, et al. Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase\u00a02 (TYK2). J Med Chem. 2019;62(20):8953\u201372.","journal-title":"J Med Chem"},{"issue":"22","key":"1727_CR50","doi-asserted-by":"publisher","first-page":"12329","DOI":"10.1073\/pnas.210244497","volume":"97","author":"JS Mitcheson","year":"2000","unstructured":"Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000;97(22):12329\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1727_CR51","doi-asserted-by":"crossref","unstructured":"Ucpinar S, Kwan J, Hoffman J, et al. Pharmacokinetic and pharmacodynamic characteristics of ESK-001, an oral allosteric TYK2 inhibitor, in phase\u00a01\u00a0healthy volunteer trials [poster 53968]. In: American Academy of Dermatology (AAD) annual meeting; March 8\u201312, 2024; San Diego, CA, USA.","DOI":"10.1016\/j.jaad.2024.07.1107"},{"issue":"2","key":"1727_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000292","volume":"2","author":"T Rose","year":"2016","unstructured":"Rose T, Szelinski F, Lisney A, et al. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren\u2019s syndrome. RMD Open. 2016;2(2):e000292.","journal-title":"RMD Open"},{"issue":"1","key":"1727_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001934","volume":"8","author":"M Graf","year":"2022","unstructured":"Graf M, von Stuckrad SL, Uruha A, et al. SIGLEC1 enables straightforward assessment of type\u00a0I interferon activity in idiopathic inflammatory myopathies. RMD Open. 2022;8(1):e001934.","journal-title":"RMD Open"},{"issue":"1","key":"1727_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2025.10.005","volume":"94","author":"KA Papp","year":"2026","unstructured":"Papp KA, Jacobs S, Sofen H, et al. Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: results from the 52-week open-label extension period of the phase\u00a02 STRIDE study. J Am Acad Dermatol. 2026;94(1):187\u201395.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01727-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01727-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01727-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:03:01Z","timestamp":1780588981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01727-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01727-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W Armstrong has served as a research investigator, scientific adviser, or speaker for AbbVie, Alumis Inc., Bristol Myers Squibb, Eli Lilly, Galderma, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun, Takeda, and UCB Pharma. James G Krueger has received institutional grant support from AbbVie, Amgen, Artax Biopharma, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, ONO-Pharma, Oruka Therapeutics, Pfizer, Provectus, Regeneron, SUDO Bio, Takeda, UCB Pharma, Ventyx, Vitae, and Zomagen; and has received fees for consulting from AbbVie, Allergan, Almirall, Alumis Inc., Amgen, Artax Biopharma, Aristea, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Calliditas, CSL Behring, Eli Lilly, Escalier, Evommune, Incyte, Innovaderm, Janssen, Kymera Therapeutics, Kyowa Kirin, MC2 Therapeutics, Merck, MoonLake Immunotherapeutics, Navigator Medicines, Novartis, Nuvig Therapeutics, Organon, Ortho Dermatologics, Oruka Therapeutics, Pfizer, Sanofi, Schrodinger, Sun Pharma, Takeda, Target-Derm, UCB Pharma, UNION Therapeutics, Valeant, and Ventyx. Bruce E Strober has served as a consultant and received honoraria from AbbVie, Almirall, Alumis Inc., Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, CorEvitas, Dermavant, Eli Lilly, Immunovant, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Neurocrine Biosciences, Novartis, Oruka Therapeutics, Pfizer, Protagonist Therapeutics, RAPT Therapeutics, Regeneron, Sanofi-Genzyme, selectION, Takeda, and UCB Pharma; has stock options in Mindera Health and selectION; has served as a speaker for AbbVie, Arcutis, Eli Lilly, Incyte, Johnson & Johnson, Regeneron, and Sanofi-Genzyme; served as scientific codirector and received consulting fees from CorEvitas Psoriasis Registry; and served as an investigator for CorEvitas Psoriasis and GPP Registries, Incyte, Oruka Therapeutics, and Takeda. Linda F Stein Gold has served as an advisor, investigator, and\/or speaker for AbbVie, Alumis Inc., Amgen, Arcutis, Eli Lilly, Galderma, Incyte, Kymera, LEO Pharma, Johnson & Johnson, Regeneron, Sanofi, and Takeda. Seemal R Desai has served as a consultant and\/or investigator for AbbVie, Alumis Inc., Arcutis, Eli Lilly, Incyte, L\u2019Oreal, Pfizer, and other organizations; and held multiple leadership positions within dermatology and other specialties. Elisa Muscianisi, Yuri Klyachkin, Sibel Ucpinar, and Mera K Tilley are employees and shareholders of Alumis Inc. Andrew Blauvelt has served as a speaker and received honoraria for Almirall, Eli Lilly, LEO Pharma, Sanofi, and UCB Pharma; has served as a scientific adviser and received honoraria for AbbVie, Almirall, Alumis Inc., Amgen, Anaptysbio, Apogee, Arcutis, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Oruka Therapeutics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB Pharma; and owns stock in Lipidio and Oruka Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}